Search
MK-3577
go.drugbank.com/drugs/DB14957InvestigationalMK-3577 is under investigation in clinical trial NCT00868790 (A Study of the Safety and Efficacy of MK-3577 in Participants With Type 2 Diabetes Mellitus (MK-3577-009)).
G305
go.drugbank.com/drugs/DB17292InvestigationalG305 is a [recombinant NY-ESO-1 protein] plus glucopyranosyl lipid A (GLA) in a stable emulsion (SE). G305 is an active component of CMB305 along with [LV305].[L47346]
CDX-6512
go.drugbank.com/drugs/DB17841ExperimentalDeveloped by Codexis, it is being investigated for the treatment of homocystinuria And Maple Syrup Urine Disease.[L46651, L46656]
Hemoglobin glutamer-256 (human)
go.drugbank.com/drugs/DB19285InvestigationalHemoglobin glutamer-256 (human) is under investigation in clinical trial NCT00076648 (Safety and Efficacy of Polyheme(r) in Hemorrhagic Shock Following Traumatic Injuries Beginning in the Pre-hospital
AGG-523
go.drugbank.com/drugs/DB15460InvestigationalAGG-523 is under investigation in clinical trial NCT00380900 (Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Ascending Doses in Healthy subjects and in subjects
Apricoxib
go.drugbank.com/drugs/DB12378InvestigationalApricoxib has been used in trials studying the treatment and prevention of Lung Cancer, Breast Cancer, Pancreatic Cancer, Non Small Cell Lung Cancer, and Metastatic Pancreatic Cancer, among others.
Sonolisib
go.drugbank.com/drugs/DB12601InvestigationalSonolisib has been used in trials studying the treatment of Glioblastoma, Prostate Cancer, Advanced Solid Tumors, Advanced BRAF-mutant Cancers, and Non Small Cell Lung Cancer (NSCLC), among others.
AVI-4065
go.drugbank.com/drugs/DB05620InvestigationalAfter phase II trials it was cancelled due to lack of potency. [L2917]
TAK-754
go.drugbank.com/drugs/DB17850InvestigationalDeveloped by Takeda, it is being investigated for the treatment of hemophilia A.[A259831]
Nivatrotamab
go.drugbank.com/drugs/DB16654InvestigationalNivatrotamab is under investigation in clinical trial NCT03860207 (Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3f8-bsab) in Patients With Relapsed/refractory Neuroblastoma,